How Agentic AI Is Transforming Healthcare: From Diagnostics to Drug Discovery (2026)

Healthcare AI Use Cases at a Glance: 10 Applications Hospitals Use Today

Healthcare AI is not one thing. It covers everything from a chatbot answering appointment questions to an autonomous system that reads a CT scan, cross-references the patient's medication history, and drafts a preliminary radiology report before a specialist even opens the file. The range is enormous, and so is the variation in maturity, risk, and return.

Before diving into how each of these healthcare AI use cases actually works in practice, here is the full landscape in one place.

A few things stand out when you look at this table as a whole. The use cases with the highest ROI and lowest implementation difficulty, like clinical documentation and prior authorization, are already widely deployed. That is where your quickest wins are. The use cases with the most transformational potential, drug discovery and AI-assisted treatment planning, carry the highest compliance burden and integration complexity. Those require longer runways and more specialized partners.

Remote monitoring sits in an interesting middle ground. The underlying technology is mature, wearable hardware is widely available, and the clinical evidence for reducing readmissions is strong. What holds most health systems back is not the AI itself but the operational redesign required to act on what the AI flags.

Every one of these use cases gets more capable as the AI moves from a single-task model toward an agentic architecture that reasons across multiple data sources and executes workflows rather than just producing outputs. The rest of this article breaks down what that actually looks like in production.

Healthcare AI Use Cases in Clinical Diagnostics, Medical Imaging, and Genomics

Two areas where AI has moved from interesting prototype to clinical reality are radiology and molecular pathology. Both follow a similar pattern: AI handles the volume, the sorting, and the pattern recognition, while the clinician owns the diagnosis.

Medical Imaging: How Data Actually Moves Through the System

When a patient gets a CT scan, the DICOM files hit the PACS server. In a hospital running medical imaging AI, those studies don't sit in a queue waiting for a radiologist to work through them sequentially. The algorithm reads every study in the batch, assigns a priority score based on detected findings, and pushes likely strokes, pulmonary embolisms, and critical hemorrhages to the top of the worklist. Routine screenings wait. The urgent ones don't.

The radiologist opens the flagged study and sees the AI overlay: bounding boxes, segmentation masks, confidence scores on the findings. They review the AI output against the raw images, check the patient's prior imaging and medication history pulled from the EHR, and either confirm or override. That's the first read. Quality checks still happen, especially for high-risk findings, and some institutions run a second radiologist review on AI-flagged cases before results go to the referring physician.

The metrics that matter here are specific. Turnaround time for standard studies. Triage speed on suspected strokes, where time-to-treatment directly affects outcomes. Sensitivity lift on PE detection compared to unaided reads. Viz.ai, for example, reports that its large vessel occlusion detection tool reduces time from imaging to treatment decision in stroke cases. Real performance in production, not benchmark numbers.

The key point: the AI surfaces findings. The radiologist makes the diagnosis. That boundary isn't optional.

Pathology and Genomics: A Cancer Workflow, Step by Step

Take colorectal cancer as a concrete example. A patient presents with a suspicious lesion. A biopsy produces a tissue slide.

In a digital pathology workflow, the whole-slide image gets analyzed by an AI system trained on thousands of annotated cases. The algorithm identifies tumor regions, grades the tissue, flags areas that warrant closer attention, and quantifies features a human pathologist would otherwise score manually. Paige AI's FDA-authorized platform does exactly this, reducing the cognitive load on pathologists who are reviewing hundreds of slides in a day.

But the workflow doesn't stop at the slide. Once a colorectal tumor is confirmed, the next question is molecular profile. What mutations does it carry? MSI status? KRAS, NRAS, BRAF mutations? Systems connected to genomic data layers take the pathology finding and automatically suggest a targeted biomarker panel, flagging which molecular tests are clinically relevant for this tumor type and stage.

When those genomic results come back, the AI cross-references the mutation profile against approved therapies and active clinical trials. This is where clinical trial matching becomes a real workflow function, not just a research concept. A patient with a specific BRAF mutation and MSS status has a different set of relevant trials than one with MMR deficiency. The system surfaces that automatically rather than requiring an oncologist to manually search registries.

The step-by-step looks like this:

• Slide analysis: AI grades tumor tissue and identifies key morphological features
• Biomarker suggestion: System recommends molecular testing based on tumor type, stage, and clinical guidelines
• Genomic profiling: Lab runs the panel, results feed back into the platform
• Treatment and trial matching: AI maps the molecular profile to approved therapies and eligible trials, ranked by evidence strength

Again, the oncologist reviews every recommendation. They decide what gets ordered, what gets discussed with the patient, and what treatment path is taken. The AI compresses the time between biopsy and actionable clinical decision. It doesn't make the decision.

That distinction matters for trust. Clinicians who are skeptical of AI in diagnostics are right to ask where the accountability sits. Building AI workflows that keep the clinician in the decision seat, with full transparency into what the algorithm flagged and why, is what separates deployable clinical AI from technology that stays in the pilot phase indefinitely.

AI Drug Discovery Use Cases and AI-Powered Treatment Planning

AI drug discovery sits in a fundamentally different category from clinical decision support, and conflating the two leads to bad product decisions. One operates in research labs and computational pipelines. The other operates at the bedside, where a clinician needs a recommendation backed by evidence before they see the next patient. Both matter. Neither replaces the other.

Start with the research side. The discovery workflow runs in a fairly consistent sequence regardless of which platform you use: target identification, structure prediction, molecule generation, virtual screening, lab validation, and candidate prioritization. AI compresses the iteration cycles between these stages, not the stages themselves.

Target identification used to require years of literature review and experimental probing to find a protein worth attacking. Google DeepMind's AlphaFold changed that equation by predicting the 3D structure of over 200 million proteins, giving researchers a structural map they can query computationally rather than experimentally. Once you have a viable target with a known binding site, molecule design shifts from manual chemistry to generative modeling. AI agents propose candidate molecules optimized across multiple constraints simultaneously: efficacy, selectivity, synthesizability, and toxicity profiles.

That brings you to virtual screening. Instead of physically synthesizing hundreds of compounds to test binding affinity, AI ranks candidates computationally. The ones that survive get passed to wet-lab validation. This is the part that does not disappear. Biology is messy, and computational predictions still need experimental confirmation. What changes is that you arrive at lab validation with a much shorter list of high-confidence candidates rather than a broad, expensive shotgun approach.

Insilico Medicine's work on idiopathic pulmonary fibrosis makes this concrete. Their AI drug discovery platform identified a novel target and produced a clinical candidate in under 18 months, a process that typically consumes four to five years. That candidate, INS018_055, reached Phase II trials, making it one of the first AI-discovered drugs to hit mid-stage clinical testing. The wet lab did not go away. The number of failed iterations before reaching a viable candidate dropped sharply.

Now shift to the clinical side, where the application looks completely different.

Take oncology. A patient presents with a rare solid tumor. Their oncologist needs to know which approved therapies match their specific molecular profile, which clinical guidelines apply, and whether any active trials might be a better option than standard of care. Manually cross-referencing genomic sequencing results against treatment guidelines, published evidence, and open trial databases can take days or weeks in a busy practice.

Platforms like Tempus AI tackle this directly. They ingest genomic, transcriptomic, and clinical data from the patient record and match it against a dataset built from millions of de-identified cases. The output is not a diagnosis. It is a ranked set of therapy options tied to the patient's specific molecular markers, with supporting evidence attached, ready for the oncologist to review. Clinical trial matching runs as part of that same workflow, surfacing trials the patient qualifies for based on eligibility criteria pulled directly from the clinical record.

The measurable outcome here is real. Health systems using AI-assisted trial matching report enrollment rates increasing by 30 to 50 percent compared to manual identification processes, largely because eligible patients were simply never identified under the previous workflow.

The clinician still makes the call. The AI handles the data assembly and evidence synthesis that previously ate hours of a physician's time.

That distinction matters for anyone building or evaluating healthcare AI: research-stage tools live in computational biology and cheminformatics pipelines, while clinical decision support lives inside EHR workflows, subject to different regulatory scrutiny, different latency requirements, and a fundamentally different definition of what a wrong answer costs.

Clinical Documentation Automation and Administrative Healthcare AI Use Cases

Clinical documentation automation sits at the intersection of where AI delivers immediate, measurable value and where clinicians feel the most daily pain. The average physician spends roughly two hours documenting for every hour of direct patient care. That math is unsustainable, and AI is starting to fix it.

Ambient listening tools like Microsoft DAX Copilot capture patient-physician conversations in real time and convert them into structured clinical notes. But the more capable systems go further than transcription. They draft SOAP notes with appropriate ICD-10 and CPT codes, extract orders from the conversation, pre-populate EHR fields, flag overdue screenings, and generate plain-language after-visit summaries for patients. The clinician reviews, adjusts, and signs off. The AI handles the mechanics.

That last part matters. These systems assist, not replace. High-stakes decisions, edge cases, and anything requiring clinical judgment still sits with the physician. What changes is how much time they spend on paperwork versus thinking.

On the administrative side, the before-and-after picture for prior authorization is stark. Before AI: a staff member manually pulls clinical notes, checks payer criteria, submits the request, waits for a response, and handles denials through a separate appeals process that can take days. After AI: the system automatically gathers supporting documentation, checks it against payer rules, submits the request, and flags only the exceptions or appeals for human review. Turnaround times drop from days to hours. Denial rates fall because submissions arrive complete and correctly coded the first time.

Revenue cycle automation follows the same pattern. AI handles claims review, spots coding errors before submission, predicts which claims carry high denial risk, and routes those for human review before they ever reach the payer. Staff time shifts from reactive denial management to exception handling and appeals, which require actual judgment. The business metrics that improve include faster days in accounts receivable, lower denial rates typically in the range of 20 to 40 percent reduction, and reduced time spent per claim by billing staff.

Human oversight does not disappear here. Appeals involving clinical necessity determinations, high-dollar claims, or ambiguous payer policies still need a trained human to review and respond. AI handles the volume work. People handle the judgment calls.

For technical readers thinking about how to actually build this: FHIR compatibility is non-negotiable. Your AI layer needs to read from and write back to EHR systems through standardized APIs, whether that is Epic's FHIR endpoints, Cerner's, or a third-party integration layer. Audit logs capturing every AI-generated suggestion, every human modification, and every final decision are required for both regulatory compliance and model improvement. Model monitoring should track accuracy drift over time, particularly as payer rules change or coding standards update. Without that feedback loop, your automation quietly degrades.

The payoff for getting this right is real: less administrative overhead, faster revenue collection, and clinicians who spend more time on actual care.

Healthcare AI Use Cases in Triage, Remote Patient Monitoring, and Virtual Care

Emergency departments run on one scarce resource: time. When a patient walks in at 2 AM with chest pain, the difference between a 40-minute wait and a 12-minute escalation to a cardiologist can be the difference between a full recovery and permanent damage.

Agentic triage systems don't just replace a paper form. They pull vitals from bedside monitors, parse the chief complaint, scan medication history and prior ED visits, cross-reference current bed capacity, and assign an acuity score in under 60 seconds. Bon Secours Mercy Health deployed an AI triage model across its ED network and reported a 30% reduction in door-to-provider time alongside measurably faster sepsis escalation, because the system flags lactate trends and SIRS criteria before the triage nurse finishes the intake interview. That's not a rounding benefit. Missed sepsis within the first hour costs lives, and faster acuity sorting changes that math directly.

Beyond the ED, care navigation AI handles a quieter but equally important job: getting patients to the right provider without burning 45 minutes on hold. These systems process symptoms, insurance status, and appointment availability simultaneously, routing patients to the correct specialty or urgent care setting rather than defaulting to the ER for every non-emergent issue.

Remote patient monitoring is where the operational depth gets serious. Remote patient monitoring platforms now organize alert logic by condition rather than applying a single threshold across all patients.

For heart failure patients, a weight gain of more than 2 pounds in 24 hours or 5 pounds in 72 hours triggers a tiered response: an automated app notification first, followed by a nurse review queue if the patient doesn't acknowledge it within 4 hours, and a direct provider call if BNP levels from a connected device also trend upward. Programs using this logic have cut 30-day heart failure readmissions by 20 to 25 percent in published trials.

Diabetes monitoring works differently. Continuous glucose monitors feed data into AI models that flag hypoglycemic patterns before they become emergencies, alert care coordinators when time-in-range drops below 70% for 3 consecutive days, and push medication adherence reminders calibrated to the patient's own behavioral patterns. The outcome isn't just better glucose control. It's fewer nurse escalation calls because the system handles first-line outreach automatically.

COPD patients on remote patient monitoring trigger alerts when peak flow readings drop more than 20% below personal baseline or when oxygen saturation dips below 92% during activity. The escalation logic routes mild deviations to an asynchronous nurse message, moderate deviations to a same-day telehealth visit, and severe readings directly to emergency services. One study across a 3,000-patient COPD cohort found this approach saved an average of 2.3 nurse hours per patient per month by eliminating unnecessary check-in calls for stable patients.

Virtual nursing handles what remote patient monitoring surfaces. AI-assisted virtual nurses review flagged alerts, conduct video assessments, adjust care plans within protocol, and document everything directly into the EHR without requiring a floor nurse to drive the interaction. Hospitals running virtual nursing programs have reported covering 4 to 6 patients per virtual nurse hour, compared to 1 to 2 for traditional bedside rounds on monitored patients.

Patient engagement chatbots and call center automation close the loop on the intent-driven side of care. Post-discharge chatbots send structured follow-up questions at 24, 48, and 72 hours, flag deterioration signals from patient responses, and schedule follow-up appointments without routing through a call center. On the call center side, AI handles appointment scheduling, prescription refill requests, and insurance verification autonomously, with human agents receiving only the escalations that require judgment. Health systems using this model have reported 35 to 40% reductions in inbound call volume without cutting patient access.

Healthcare AI Use Cases, Compliance, and a 90-Day Roadmap

Compliance is not a final checkbox before launch. It is the gate your pilot either passes or doesn't. Skip it early and you will rebuild everything later, under pressure, after someone important has already said yes to production deployment.

Here is what actually matters for healthcare AI use cases in 2026.

HIPAA and BAAs

Every AI vendor that touches Protected Health Information must sign a Business Associate Agreement. That includes cloud-hosted foundation models from OpenAI, Google, and Anthropic. Most healthcare teams assume their cloud provider's standard terms cover them. They don't. Get the BAA before any patient data moves into any pipeline.

Apply the Minimum Necessary standard aggressively. Your agentic system should pull only the data fields it actually needs for the task at hand, not the full patient record because it's convenient.

FDA Software as a Medical Device

If your AI influences a clinical decision, the FDA likely considers it Software as a Medical Device. The classification determines your regulatory pathway: 510(k), De Novo, or PMA. The higher the autonomy, the higher the scrutiny. Administrative tools like documentation automation sit in a different risk tier than a diagnostic agent that recommends treatment without a physician in the loop.

Predetermined Change Control Plans now let you pre-specify how your model will be updated post-market, which removes the need to resubmit every time you retrain. If continuous learning is part of your architecture, build a PCCP into your regulatory strategy from day one.

EU MDR and the EU AI Act

In Europe, clinical decision support software that shapes diagnosis or treatment qualifies as a medical device under EU MDR, which means CE marking and clinical evaluation are mandatory. Layer on top of that the EU AI Act, which classifies healthcare AI as high-risk and requires conformity assessments, human oversight provisions, and ongoing post-market surveillance. For European deployments, self-hosted infrastructure is often the practical answer because patient data cannot leave the organization's environment without creating GDPR exposure.

Pilot Prioritization: Where to Start

Start at the top of that list. Clinical documentation gives you fast wins, immediate clinician buy-in, and minimal regulatory exposure while your compliance infrastructure matures.

Build vs. Partner: The Honest Checklist

Answer these questions before committing to an approach.

Build in-house if:

• You have an existing ML engineering team with healthcare domain experience
• Your workflows are highly proprietary and no vendor offers adequate customization
• You can absorb an 18 to 24 month timeline and $2M+ budget
• Full data control is a hard requirement with no flexibility

Use a platform vendor if:

• You need a point solution live in under 90 days
• A vendor already covers your use case (DAX for documentation, Waystar for prior auth)
• Your IT team cannot support custom model infrastructure
• Budget is under $500K annually

Partner with a development firm if:

• You need custom integrations across multiple EHR systems using FHIR
• You want retrieval-augmented generation grounded in your own clinical data
• You need a hybrid: a vendor model plus custom orchestration logic built around your workflows
• Regulatory accountability needs to be shared, not entirely yours

Most mid-size health systems land in the third column. The platform won't bend far enough and an in-house build takes too long.

The 90-Day Roadmap

Month 1: Assess and Select

Owner: Chief Medical Information Officer plus Head of Compliance

Deliverables: workflow audit covering documentation, prior auth, and scheduling volumes; vendor shortlist with BAA status confirmed; pilot scope document with named clinician cohort (20 to 50 users); HIPAA Security Risk Assessment initiated.

Meeting cadence: weekly steering call with CMIO, IT lead, and compliance officer.

Validation checkpoint: pilot scope approved by legal and clinical leadership before any PHI moves into a test environment.

Risk control: no production patient data in any vendor system without a signed BAA and completed security review.

Success metric: pilot use case selected, vendor contracted, and cohort confirmed by day 30.

Month 2: Deploy and Measure

Owner: IT Project Lead plus Clinical Champion

Deliverables: pilot live with defined cohort, baseline metrics captured (time per encounter, error rates, clinician satisfaction scores), edge case log started, first continuous monitoring dashboard active.

Meeting cadence: biweekly data review with clinical champion and IT lead, weekly check-in with pilot users.

Validation checkpoint: at day 45, review accuracy and satisfaction data. If accuracy falls below agreed threshold, pause and investigate before expanding.

Risk control: human review required on all AI outputs during pilot phase. No autonomous actions without clinician confirmation.

Success metric: measurable time savings per encounter documented, at least 70% clinician satisfaction in pilot cohort.

Month 3: Expand and Govern

Owner: CMO plus CIO

Deliverables: rollout plan for next department or use case, AI governance policy drafted (who reviews outputs, how errors get reported, how models get updated), compliance evidence package assembled for regulatory requirements, next-phase roadmap approved.

Meeting cadence: monthly governance review at executive level, ongoing biweekly operational reviews.

Validation checkpoint: governance policy signed off by legal, compliance, and clinical leadership before broader rollout.

Risk control: SaMD classification review completed if expanding to any diagnostic function. EU MDR conformity assessment scoped if European operations are involved.

Success metric: governance policy live, next pilot use case scoped, and ROI from Month 2 documented and presented to leadership by day 90.

Ninety days gets you from zero to a validated pilot with governance in place. That is a credible foundation, not a finished product. The real work starts in Month 4, when you decide how far to push the autonomy dial.

Conclusion

The strongest healthcare AI use cases share three traits: they target a workflow that genuinely hurts, they have enough clean data to train and validate on, and they keep a clinician in the decision loop where the stakes are high. Strip out any one of those three and you are building toward a proof-of-concept that never scales.

Healthcare AI compliance is not a final checkbox before go-live. It shapes your architecture from day one, covering data access, model auditability, and how you handle edge cases when the system is wrong.

Diagnostics, clinical documentation, and remote patient monitoring tend to be where organizations find traction first among healthcare AI use cases. The ROI is measurable, the workflows are well-defined, and the regulatory path is clearer than in more experimental applications. That is a reasonable place to start.

Pick one priority workflow. Map the pain, the data you actually have, and who owns the clinical sign-off. If you want help designing a compliant pilot or a production-ready architecture, the Brilworks team is worth a conversation.